The International AIDS Vaccine Initiative (IAVI) has made a significant move, transferring crucial samples from its Human Immunology Laboratory (HIL) in the UK to the Aurum Institute in Johannesburg, South Africa. This strategic decision underscores IAVI's commitment to strengthening research capabilities in Africa and India while intensifying efforts to combat HIV/AIDS and emerging infectious diseases (EIDs).

For over two decades, the IAVI HIL has been pivotal in supporting scientific laboratories across Africa and India, facilitating groundbreaking HIV/AIDS research and clinical trials. The relocation of samples from African epidemiological studies and HIV vaccine trials marks a milestone in empowering local research communities and fostering sustainable research activities on the continent. These samples, originating from landmark studies supported by organisations like USAID, have been instrumental in driving scientific breakthroughs, reshaping HIV vaccine development and sparking innovative research initiatives worldwide.

Despite the closure of the HIL operations, IAVI remains steadfast in its mission to advance vaccine research and combat infectious diseases. A dedicated team in the UK will continue assay work for emerging infectious diseases vaccine trials and transfer technology to African laboratories, ensuring uninterrupted research efforts. Additionally, IAVI is launching a new research program focused on antimicrobial resistance (AMR), demonstrating its commitment to addressing global health challenges. Through collaborative partnerships and strategic initiatives, IAVI is driving progress towards effective vaccines and therapeutic solutions for HIV/AIDS, tuberculosis, and other infectious diseases, reaffirming its dedication to global health equity and collaborative research.

 

Article by Nyokabi Wanjiku

Photo/IAVI

https://www.iavi.org/features/iavis-human-immunology-lab-sample-relocation/